Supreme Court Quashes Rajasthan Village Renaming, Says Government Must Follow its Own Policy || NCLAT: NCLT Can Order Forensic Audit on its Own, No Separate Application Required || NCLAT Reiterates That IBC Cannot be Invoked as a Recovery Tool for Contractual Disputes || Delhi HC: DRI or Central Revenues Control Lab Presence in Delhi Alone Does Not Confer Jurisdiction || Delhi High Court: Software Receipts Not Taxable on PE Basis Already Rejected by ITAT || Delhi High Court: Statutory Appeals Cannot Be Denied Due to DRAT Vacancies or Administrative Delays || J&K&L HC: Failure to Frame Limitation Issue Not Fatal; Courts May Examine Limitation Suo Motu || Bombay HC: Preventing Feeding Stray Dogs at Society or Bus Stop is Not 'Wrongful Restraint' || Gujarat HC: Not All Injuries Reduce Earning Capacity; Functional Disability Must Be Assessed || Delhi HC: Framing of Charges is Interlocutory and Not Appealable under Section 21 of NIA Act

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :